



STATEMENT

FAES FARMA and INVIDA (MENARINI Group) sign an agreement to commercialize bilastine in 17 countries in Asia – Pacific

Both companies have signed an agreement covering countries as important as China and Australia, along with other relevant markets such as Philippines, Vietnam, Thailand, Singapore, Taiwan and Malaysia.

The region is one of the largest anti-histamine markets and enjoys a double digit annual growth rate.

INVIDA is one of the commercially strongest pharmaceutical companies in the region, with a sales and promotion force exceeding 3.500 people.

Sales forecasts estimations shared by the two partners estimate capturing an antihistamine market share of up to 15 %.

This agreement will reinforce the partnership between FAES and MENARINI, group that recently has acquired INVIDA to strengthen its presence in Asia.

With this license, FAES gives a key step in its strategy of licensing bilastine to first class companies and building a global presence for its allergy product bilastine.

According to this agreement, FAES FARMA will receive upfront and milestone payments and will be the exclusive supplier of the Active Ingredient to INVIDA.

April 26th, 2012